UnknownPhase 3

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Mexico72 participantsStarted 2020-03-30

Plain-language summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Who can participate

Age range

40 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of T2DM * HbA1c \> 7 y \< 10 * BMI 25 - 34.9 kg/m2 * Signature of consent under information Exclusion Criteria: * Hypertension * Treated with insulin and / or loop diuretics and thiazides * T1DM * Hypotension * Any autoimmune disease * Liver disease * Women whitout birth control method * Women taking oral birth control or under hormone replacement therapy * Woman pregnant or breastfeeding * Untreated thyroid disease * Patients with a cardiovascular disease that contraindicates the use of this pharmacological class * Glomerular filtration rate \<60ml/min (Cockcroft-Gault)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Pulse wave velocity

Timeframe: 7 days

Trial details

NCT IDNCT05109949

SponsorCentro Universitario de Ciencias de la Salud, Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-01

View on ClinicalTrials.gov More Diabetes Mellitus Type 2 Without Complication trials